10-K: MeiraGTx Holdings PLC Announces 2024 Financial Results and Provides Business Update

MeiraGTx Holdings PLC reports its financial results for the year ended December 31, 2024, highlighting progress in clinical programs and strategic collaborations.

Summary

• MeiraGTx Holdings PLC, a clinical-stage genetic medicines company, has released its financial results for the year ended December 31, 2024.
• The company incurred a net loss of $147.8 million in 2024, compared to a net loss of $84.0 million in 2023.
• As of December 31, 2024, MeiraGTx had cash, cash equivalents, and restricted cash totaling $105.7 million.
• The company anticipates that its current financial resources, along with expected proceeds from a strategic collaboration with Hologen Ltd, will fund operations into 2027.
• MeiraGTx is eligible to receive up to $285 million in milestones from Johnson & Johnson Innovative Medicine upon the first commercial sales of bota-vec in the U.S. and EU, and for manufacturing tech transfer.
• The company is progressing its riboswitch technology platform in metabolic disease and CAR-T for oncology and autoimmune disease.
• MeiraGTx intends to submit a Marketing Authorization Application (MAA) under exceptional circumstances for rAAV8.hRKp.AIPL1 in the UK.
• The company is engaging with the FDA to discuss a path forward for regulatory approval in the U.S. for AAV-AIPL1.
• The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-hAQP1 for the treatment of grade 2 or 3 radiation-induced xerostomia (RIX).
• A Phase 2 AQUAx2 study evaluating AAV-hAQP1 for RIX is ongoing in the U.S., Canada, and the UK.
• Preliminary data from a Phase 1 bridging study of AAV-GAD for Parkinsons disease showed safety and tolerability, with significant improvements in UPDRS Part 3 off medication score in the high dose group.
• The company has a strategic collaboration with Hologen AI, receiving $200 million upfront and up to $230 million in committed funding for the AAV-GAD program and other CNS therapies.
• Sanofi has a right of first negotiation for use of MeiraGTx's riboswitch gene regulation technology for certain Immunology and Inflammation (I&I) and Central Nervous System (CNS) targets, as well as for GLP-1 and other gut peptides for metabolic disease, and for the Phase 2 xerostomia program.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments in clinical trials and strategic collaborations, the increased net loss and reliance on future funding indicate potential financial challenges.

Positives

• Strategic collaboration with Hologen AI provides significant upfront funding and committed investment for CNS therapies.
• FDA granted RMAT designation to AAV-hAQP1 for RIX, potentially accelerating development.
• Positive preliminary data from AAV-GAD Phase 1 bridging study in Parkinsons disease.
• Intent to submit a Marketing Authorization Application (MAA) under exceptional circumstances for rAAV8. hRKp.AIPL1 based on the results from the 11 treated children with no further clinical data required.
• Sanofi has a right of first negotiation for MeiraGTx's riboswitch gene regulation technology.

Negatives

• Net loss increased significantly in 2024 compared to 2023.
• Reliance on milestone payments from collaborations introduces uncertainty.
• The FDA's rare pediatric disease priority voucher program began to sunset on December 20, 2024, after Congress failed to pass a continuing resolution package that included its reauthorization.

Risks

• The company may not be able to successfully complete large-scale, pivotal clinical trials, obtain marketing approval, manufacture product at a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization.
• The company may not have sufficient cash flows or cash on hand to satisfy our debt obligations or covenants under our financing arrangements, or we may not be able to effectively manage our business in compliance with such covenants.
• The company is heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.
• The affected populations for our product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.
• The company and our contract manufacturers for plasmid are subject to significant regulation with respect to manufacturing our products. Our manufacturing facilities and the third-party manufacturing facilities which we rely on may not continue to meet regulatory requirements and have limited capacity.
• The company faces significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.
• The company depends on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our product candidates.
• If we are unable to obtain and maintain patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
• The company may need to increase or decrease the size of our organization, and we may experience difficulties in managing these organizational changes, which could disrupt our operations.
• The company's future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.

Future Outlook

MeiraGTx anticipates that its current financial resources, along with expected proceeds from a strategic collaboration with Hologen Ltd, will fund operations into 2027. The company is eligible to receive up to $285 million in milestones from Johnson & Johnson Innovative Medicine upon the first commercial sales of bota-vec in the U.S. and EU, and for manufacturing tech transfer.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. This is true in the field of gene therapy generally, and in the treatments for our key disease areas.

Comparison to Industry Standards

• The FDA has approved the first gene treatment for RPE65 -associated retinal dystrophy, Luxturna, a commercially available product developed by Spark Therapeutics, Inc., which was purchased by Roche.
• We are aware of other ALS gene therapies utilizing different treatment mechanisms to treat different genetically defined subsets of ALS patients, as well as gene therapy product candidates being developed for the treatment of Parkinsons disease, including those being developed by Voyager Therapeutics, Inc. and Eli Lilly and Company.

Related Party Transactions

• The document discusses related party transactions with Johnson & Johnson Innovative Medicine and Sanofi Foreign Participations B.V.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings.
• Employees: Potential for job creation or reduction based on company performance.
• Patients: Potential for new treatments for serious disorders.
• Collaborators: Continued collaboration on research and development programs.

Next Steps

• Continue enrollment and dosing in the Phase 2 AQUAx2 study for AAV-hAQP1.
• Submit a Marketing Authorization Application (MAA) under exceptional circumstances for rAAV8. hRKp.AIPL1 in the UK.
• Engage with the FDA to discuss a path forward for regulatory approval in the U.S. for AAV-AIPL1.
• Continue to progress our riboswitch technology platform in multiple potential indications, with an initial focus on obesity and metabolic disease and CAR-T for oncology and autoimmune disease.
• Initiate first-in-human studies using the riboswitch platform in 2025.
• Data from the Phase 3 LUMEOS trial of botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa in collaboration with Johnson & Johnson Innovative Medicine is expected in 2025.

Key Dates